
Staying One Step Ahead of Resistance
How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium
Pathways to infection resilience
will take place on 3 - 4 September.

How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

A team of researchers from Hamburg, Berlin, Göttingen and Hannover has provided evidence of possible cross-protection offered by an already authorised Zaire Ebola virus vaccine.

Memory B cells play a key role in adapting to new coronavirus variants
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Baydemir I, Nikolka F, Bulut Ö, Ferreira A, Kilic G, Geckin B, Kramer R, Cuenca-Escalona J, Floor E, Báez-Magaña M, Matzaraki V, Deckers J, Anbergen T, van Elsas Y, Beldman T, Moorlag S, Charlotte J de Bree L, Spanou V, Andriopoulou T, Li Y, Karagianni E, Novakovic B, Sohrabi Y, Joosten L, Hiller K, Domínguez-Andrés J
Tapken I, Rahmel-Stein K, Ehlers C, Cieri F, Detering N, Schüning T, Bjelica B, Mindermann C, Neuhoff S, Schmitt L, Leo M, Hagenacker T, Illsinger S, Di Schiavi E, Graalmann T, Petri S, Kalinke U, Claus P
Amurri L, Reynard O, Ronco I, Déri D, Pályi B, Spanier J, Skerra J, Terceve O, Larcher T, Kalinke U, Kis Z, Horvat B, Iampietro M
The project is developing iPSC-based therapies for MSMD patients, a genetic disease with mutations in the IFN-γ signaling pathway that lead to severe mycobacterial infections. The aim is to improve the treatment prognosis.
We are investigating why HCV infections sometimes heal spontaneously, but often become chronic, and why RSV infections are severe in some children. We use modern sequencing technologies to analyze the genetic characteristics of hosts and pathogens in order to understand susceptibility.
Together with the Department of Structural Biology at the University of Lübeck, human, strongly neutralizing antibodies against HEV were identified and characterized for the first time. These showed a protective effect in the mouse model and are currently being further developed for clinical application, including mRNA-based application methods.
We are investigating how genetic variants influence the risk of severe RSV infections in infants. Exome sequencing and bioinformatic analyses are used to identify causal variants in immunity genes.
Pathways to Infection Resilience
Prof. Naglaa Shoukry
University of Montreal
"Single-Cell RNA Sequencing Analysis of CD8+ T Cell-Mediated Protective Immunity During HCV Reinfection"
"Why is knowledge in regulatory science important for translational medicine and basic science?"

